View More Recent Stories
-
Piper Sandler on Procept BioRobotics Corp (PRCT): 'Compelling Setup Ahead of Near-Term Catalysts'
-
TD Cowen on Medical Supplies & Devices: 'Companies Least Affected by New Reciprocal Tariffs'
-
PROCEPT BioRobotic (PRCT): WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
-
Jefferies Reiterates Hold Rating on Procept BioRobotics Corp (PRCT)
-
PROCEPT BioRobotics Corporation (PRCT) Misses Q4 EPS by 1c
-
MedTech sector outlook for 2025: Truist Securities
-
Spruce Point short PROCEPT BioRobotics Corporation (PRCT)
-
PROCEPT BioRobotics Corporation (PRCT) Mentioned as Short at Spruce Point
-
Spruce Point short PROCEPT BioRobotics Corporation (PRCT)
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
Morgan Stanley Starts Procept BioRobotics Corp (PRCT) at Overweight, PT $105
-
Jefferies Starts Procept BioRobotics Corp (PRCT) at Hold
-
PROCEPT BioRobotics Corporation (PRCT) Prices 1.92M Share Offering at $91/sh
-
Procept BioRobotics Corp (PRCT) PT Raised to $105 at Truist Securities
-
BTIG Reiterates Neutral Rating on Procept BioRobotics Corp (PRCT)
-
PROCEPT BioRobotics Corporation (PRCT) Announces Proposed $175M Share Offering
-
PROCEPT BioRobotics Corporation (PRCT) November 70 and December 90 calls active as share price up 27%
-
PROCEPT BioRobotics Corporation (PRCT) Tops Q3 EPS by 9c
-
TD Cowen Reiterates Buy Rating on Procept BioRobotics Corp (PRCT)
-
Piper Sandler Reiterates Overweight Rating on Procept BioRobotics Corp (PRCT)
-
PROCEPT BioRobotics (PRCT) Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
-
Procept BioRobotics Corp (PRCT) PT Raised to $99 at TD Cowen
-
Procept BioRobotics Corp (PRCT) PT Raised to $95 at Truist Securities
-
Procept BioRobotics Corp (PRCT) PT Raised to $94 at BofA Securities
-
TD Cowen Reiterates Buy Rating on Procept BioRobotics Corp (PRCT)
-
Truist Securities Reiterates Buy Rating on Procept BioRobotics Corp (PRCT)
-
PROCEPT BioRobotics Corporation (PRCT) Announces FDA Clearance of the HYDROS Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
-
PROCEPT BioRobotics Corporation (PRCT) Tops Q2 EPS by 2c
-
PROCEPT BioRobotics Corporation (PRCT) August 55, 60 and 65 puts active
-
Procept BioRobotics Corp (PRCT) PT Raised to $79 at Truist Securities
-
TD Cowen Reiterates Buy Rating on Procept BioRobotics Corp (PRCT)
-
PROCEPT BioRobotics (PRCT) Announces New CPT Category I Code from the American Medical Association for Aquablation therapy
-
Analyst weighs in on current investor sentiment in MedTech sector
-
Top 4 AI robotics stocks set to soar (Part 3)

